Vous avez cherché: dermatologic (Anglais - Maltais)

dermatologic reactions
reazzjonijiet dermatoloġiċi

dermatologic reactions (f)
reazzjonijiet dermatoloġiċi (f)

remote site dermatologic reaction
reazzjoni dermatoloġika f’sit il-bogħod miż-żona kkurata

dermatologic reactions and soft tissue toxicity
reazzjonijiet dermatoloġiċi u tossiċità tat-tessut l-artab

angioedema and severe dermatologic reactions have been reported (see section 4.8).
anġjoedema u reazzjonijiet severi tal-ġilda ġew irrappurtati (ara sezzjoni 4.8).

in patients who experience a severe dermatologic reaction, vemurafenib treatment should be permanently discontinued.
f’pazjenti li jkollhom reazzjoni dermatoloġika severa, kura b’vemurafenib għandha titwaqqaf b’mod permanenti.

rare cases of remote site dermatologic drug reactions, including erythema multiforme, have been reported from clinical trials.
waslu rapporti minn provi kliniċi ta 'każijiet rari dwar reazzjonijiet dermatoloġiċi għal mediċina f' sit remot, li jinkludi eritema multiforme.

it is recommended that all patients receive a dermatologic evaluation prior to initiation of therapy and be monitored routinely while on therapy.
huwa rrakkomandat li l-pazjenti kollha jkollhom evalwazzjoni dermatoloġika qabel il-bidu tat-terapija u jiġu ssorveljati b’mod regolari waqt it-terapija.

early intervention (such as emollients, antibiotics) of dermatologic reactions can facilitate continuous giotrif treatment.
intervent bikri (bħal emoljenti u antibijotiċi) għal reazzjonijiet dermatoloġiċi, jista’ jiffaċilita kura kontinwa b’giotrif.

in children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.
fi tfal li jesperjenzaw feriti tax-xjuħija minħabba d-dawl bħal lentiġini jew nemex, hu rrakkomandat li jevitaw ix-xemx u li jsir follow-up dermatoloġiku anki wara t-twaqqif tat-trattament.

rare cases of remote site dermatologic reactions, including erythema multiforme, have been reported from clinical trials with imiquimod 5% cream therapy.
każijiet rari ta’ reazzjonijiet dermatoloġiċi f’siti l-bogħod miż-żona kkurata, inkluż eritema multiforme, ġew irrappurtati minn provi kliniċi b’terapija bi krema imiquimod 5%.

other possible dermatologic effects may include dryness, thickness or cracking of the skin, blisters, or occasional rash on the palms of the hands and soles of the feet.
effetti dermatoloġiċi oħra possibbli jistgħu jinkludu xuttaġni, ħxuna jew qsim tal-ġilda, infafet, jew xi kultant raxx fuq il-keffef ta’ l-idejn u l-qigħan tas-saqajn.

dermatologic evaluation should be performed on a systematic and regular basis, whenever vfend is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions.
evalwazzjoni dermatoloġika għandha titwettaq fuq bażi sistematika u regolari, kull meta vfend jitkompla minkejja l- okkorrenza ta’ leżjonijiet relatati mal-fototossiċità, biex tippermetti l-iżvelar bikri u l-immaniġġjar ta’ leżjonijiet premalinni.

if a patient develops dermatologic reactions that are grade 3 (ctcae v 4.0) or higher, or that are considered intolerable, the following dose modification is recommended:
jekk pazjent jiżviluppa reazzjonijiet dermatoloġiċi li huma ta’ grad 3 (ctcae v 4.0) jew akbar, jew li huma kkunsidrati intollerabbli, hija rakkomandata il-modifikazzjoni li ġejja fid-doża:

the most common adverse reactions (> 25%) during therapy with lapatinib plus capecitabine were gastrointestinal (diarrhoea, nausea, and vomiting) or dermatologic (palmar-plantar erythrodysesthesia [ppe] and rash).
l- aktar reazzjonijiet avversi komuni (> 25%) waqt kura b’ lapatinib ma ’ capecitabine kienu gastro- intestinali (dijarea, dardir, u rimettar) jew dermatoloġiċi (eritrodisestesja fil- pala ta 'l- id u tas- sieq [ppe] u raxx).